A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies von Sharman, Jeffrey P., Biondo, Juliana M. L., Boyer, Michelle, Fischer, Kirsten, Hallek, Michael, Jiang, Dingfeng, Kater, Arnon P., Porro Lurà, Michele, Wierda, William G.

Volltext

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax von Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lurà, Michele Porro, Kneba, Michael, Döhner, Hartmut, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan

Volltext

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia von Davids, Matthew S., Fischer, Kirsten, Robrecht, Sandra, Zhang, Can, Ahn, Inhye E., Porro Lurà, Michele, Sinai, Wendy, Chyla, Brenda, Sail, Kavita, Pesko, John, Pai, Madhavi, Komlosi, Viktor, Hallek, Michael, Brown, Jennifer R., Al-Sawaf, Othman

Volltext